Stocks and Investing
Stocks and Investing
Fri, February 21, 2014
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, February 20, 2014
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, February 19, 2014
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, February 18, 2014
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, February 17, 2014
[ 12:00 AM ] - WOPRAI
Fri, February 14, 2014
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $400 on, Feb 14th, 2014
Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $375 to $400 on, Feb 14th, 2014.
Evan has made no other calls on BIIB in the last 4 months.
There are 3 other peers that have a rating on BIIB. Out of the 3 peers that are also analyzing BIIB, 0 agree with Evan's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Evan
- Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $415 on, Tuesday, January 28th, 2014
- Christopher Marai of "Nomura" Initiated at Strong Buy and Held Target at $368 on, Wednesday, January 8th, 2014
- Christopher Raymond of "Piper Sandler" Initiated at Buy on, Tuesday, November 26th, 2013